Pharma Focus Asia

Medilink Therapeutics Announces Global License Agreement and Strategic Collaboration With Biontech for Advancing Next-generation Anti-cancer Antibody-drug Conjugates

Friday, October 13, 2023

MediLink Therapeutics, referred to as "MediLink," announced today a strategic research partnership and global licensing agreement with BioNTech SE, a forward-looking immunotherapy company specializing in innovative treatments for cancer and other serious diseases. Their collaboration is focused on developing an advanced antibody-drug conjugate candidate (ADC) designed to target the Human Epidermal Growth Factor Receptor 3 (HER3).

Per the agreement's terms, MediLink has granted BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink's ADC assets, with the exception of Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region. In return, BioNTech will provide an initial payment of $70 million to MediLink, along with potential additional payments tied to development, regulatory milestones, and commercial achievements, which could exceed $1 billion. The finalization of this agreement is contingent on meeting standard closing conditions, including clearance under the Hart-Scott-Rodino ("HSR") Antitrust Improvements Act.

HER3 is a well-known target known to be overexpressed in various cancer types, including non-small cell lung cancer and breast cancer. It is closely associated with tumor metastasis and disease progression. Furthermore, HER3 expression increases after initial drug therapy, making it a suitable candidate for cancer treatment. MediLink's ADC candidate has shown promising efficacy and safety in various preclinical tumor models, utilizing their proprietary TMALIN® technology. Preliminary clinical data also lends support to the validity of this candidate.




magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024